Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov R, Hristodorov D, Cremer C, Gresch G, Grieger E, Schenke L, Klose D, Amoury M, Woitok M, Jost E, Brümmendorf TH, Fendel R, Fischer R, Stein C, Thepen T, Barth S. Mladenov R, et al. Among authors: amoury m. Oncotarget. 2016 Oct 11;7(41):67166-67174. doi: 10.18632/oncotarget.11568. Oncotarget. 2016. PMID: 27564103 Free PMC article.
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S. Amoury M, et al. Cancer Lett. 2016 Mar 28;372(2):201-9. doi: 10.1016/j.canlet.2016.01.027. Epub 2016 Jan 21. Cancer Lett. 2016. PMID: 26806809
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S. Amoury M, et al. Int J Cancer. 2016 Aug 15;139(4):916-27. doi: 10.1002/ijc.30119. Epub 2016 Apr 15. Int J Cancer. 2016. PMID: 27037627 Free article.
Prognosis of patients with pulmonary embolism after rehabilitation.
Amoury M, Noack F, Kleeberg K, Stoevesandt D, Lehnigk B, Bethge S, Heinze V, Schlitt A. Amoury M, et al. Vasc Health Risk Manag. 2018 Aug 30;14:183-187. doi: 10.2147/VHRM.S158815. eCollection 2018. Vasc Health Risk Manag. 2018. PMID: 30214219 Free PMC article.
Feasibility and safety of rehabilitation after venous thromboembolism.
Noack F, Schmidt B, Amoury M, Stoevesandt D, Gielen S, Pflaumbaum B, Girschick C, Völler H, Schlitt A. Noack F, et al. Among authors: amoury m. Vasc Health Risk Manag. 2015 Jul 13;11:397-401. doi: 10.2147/VHRM.S81411. eCollection 2015. Vasc Health Risk Manag. 2015. PMID: 26203256 Free PMC article.
Leptin receptor signaling in T cells is required for Th17 differentiation.
Reis BS, Lee K, Fanok MH, Mascaraque C, Amoury M, Cohn LB, Rogoz A, Dallner OS, Moraes-Vieira PM, Domingos AI, Mucida D. Reis BS, et al. Among authors: amoury m. J Immunol. 2015 Jun 1;194(11):5253-60. doi: 10.4049/jimmunol.1402996. Epub 2015 Apr 27. J Immunol. 2015. PMID: 25917102 Free PMC article.
17 results